Citigroup initiated coverage on Exelixis with a new price target
$EXEL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Citigroup initiated coverage of Exelixis with a rating of Buy and set a new price target of $31.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/20/2024 | $36.00 → $40.00 | Outperform → Market Perform | BMO Capital Markets |
| 12/17/2024 | $35.00 → $39.00 | Buy → Neutral | BofA Securities |
| 10/16/2024 | $30.00 → $34.00 | Outperform | RBC Capital Mkts |
| 9/19/2024 | $30.00 | Neutral | UBS |
| 4/11/2024 | $25.00 | Overweight → Equal Weight | Barclays |
| 12/19/2023 | $27.00 | Buy | BTIG Research |
| 12/15/2023 | $31.00 | Buy | Citigroup |
| 9/26/2023 | $28.00 | Buy | H.C. Wainwright |
4 - EXELIXIS, INC. (0000939767) (Issuer)
4 - EXELIXIS, INC. (0000939767) (Issuer)
4 - EXELIXIS, INC. (0000939767) (Issuer)
BMO Capital Markets downgraded Exelixis from Outperform to Market Perform and set a new price target of $40.00 from $36.00 previously
BofA Securities downgraded Exelixis from Buy to Neutral and set a new price target of $39.00 from $35.00 previously
RBC Capital Mkts reiterated coverage of Exelixis with a rating of Outperform and set a new price target of $34.00 from $30.00 previously
- Total Revenues of $539.5 million, Cabozantinib Franchise U.S. Net Product Revenues of $478.1 million - - GAAP Diluted EPS of $0.40, Non-GAAP Diluted EPS of $0.47 - - Increasing Total Revenues and Net Product Revenues Guidance - - Favorable Ruling on Cabozantinib Patent Litigation Received from U.S. District Court - - Collaboration with Merck Expands Zanzalintinib Development Program - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the third quarter of 2024, provided an update on progress toward achieving key corporate objectives, and detailed its recent and anticipated commercial, clinical and pipeline
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2024 financial results will be released on Tuesday, October 29, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the Ev
- Total Revenues of $637.2 million, Cabozantinib Franchise U.S. Net Product Revenues of $437.6 million - - GAAP Diluted EPS of $0.77, Non-GAAP Diluted EPS of $0.84 - - U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application (sNDA) for Cabozantinib in Advanced Neuroendocrine Tumors (NET) - - Earned $150 million Cabozantinib Sales-Based Milestone from Ipsen - - Completed $450 million Stock Repurchase Program for 2024 - - Announced Additional Stock Repurchase Program for up to $500 million through the End of 2025 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the second quarter of 20
4 - EXELIXIS, INC. (0000939767) (Issuer)
4 - EXELIXIS, INC. (0000939767) (Issuer)
4 - EXELIXIS, INC. (0000939767) (Issuer)
TORONTO, Oct. 9, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE:AIAI) (OTCQB:AINMF) (Frankfurt: 8TV) a generative AI software leader in clinical trial analytics, is pleased to announce the appointment of P.J. Haley, Executive Vice President, Commercial at Exelixis, Inc. (NASDAQ:EXEL), as a director of the Company, effective October 15th, 2024. Mr. Haley will be replacing Sheetal Jaitly, who is stepping down as a director after a period of dedicated service and contributions to the Company. As NetraMark focuses on advancing its technology for late phas
– Cabozantinib franchise achieves approximately $1.630 billion in preliminary U.S. net product revenues for fiscal year 2023 – – Fiscal year 2024 net product revenues guidance of $1,650 million - $1,750 million; 2024 R&D expense guidance of $925 million - $975 million – – Appointment of two new board members, Mary C. Beckerle, Ph.D., and Gail Eckhardt, M.D., with extensive drug development and corporate governance expertise – – Implementing corporate restructuring to focus R&D resources on clinical stage and IND-enabling activities to maximize pipeline success and operational efficiency – – Board of Directors authorized $450 million share repurchase in 2024 after successful completi
-- Dr. Peterson's extensive experience includes clinical development, medical affairs, and regulatory leadership in support of innovative oncology product portfolios -- Exelixis, Inc. (NASDAQ:EXEL) today announced it has appointed Amy Peterson, M.D., its next Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer. Dr. Peterson is a veteran oncology drug development leader whose experience includes senior clinical development and operational roles at Genentech, Medivation, BeiGene and CytomX. She joins Exelixis as the company accelerates development of its product pipeline and builds on the success of its global cabozantinib oncology franchise. "With a
SC 13D/A - EXELIXIS, INC. (0000939767) (Subject)
SC 13G - EXELIXIS, INC. (0000939767) (Subject)
SC 13D/A - EXELIXIS, INC. (0000939767) (Subject)
Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-16) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 09/20/2023. Application Category: NDA, Application Number: 208692, Application Classification: Labeling
Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-14) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 07/14/2022. Application Category: NDA, Application Number: 208692, Application Classification: Efficacy
Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-12) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 09/17/2021. Application Category: NDA, Application Number: 208692, Application Classification: Efficacy
– Cabozantinib franchise achieves approximately $1.805 billion in preliminary U.S. net product revenues for fiscal year 2024 – – Fiscal year 2025 net product revenues guidance of $1.95 billion - $2.05 billion – – Presentation and webcast at 43rd Annual J.P. Morgan Healthcare Conference tomorrow, Monday, January 13th at 5:15 p.m. PT / 8:15 p.m. ET – Exelixis, Inc. (NASDAQ:EXEL) today announced its preliminary unaudited financial results for the fiscal year 2024, provided financial guidance for fiscal year 2025 and delivered an update on its business. Exelixis anticipates 2025 will be a year of clinical and regulatory execution and continued growth for its cabozantinib franchise, as wel
Exelixis, Inc. (NASDAQ:EXEL) today announced it has been notified by the U.S. Food and Drug Administration (FDA) that the supplemental New Drug Application (sNDA) for cabozantinib (CABOMETYX®) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic (epNET) will no longer be the subject of discussion at an Oncologic Drugs Advisory Committee meeting. The sNDA remains under consideration by FDA with a Prescription Drug User Fee Act action date of April 3, 2025. About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by
– Presentation to be webcast on www.exelixis.com – Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 5:15 p.m. PT / 8:15 p.m. PT. To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. Replays will also be available at the same location for at least 30 days. About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by
8-K - EXELIXIS, INC. (0000939767) (Filer)
10-Q - EXELIXIS, INC. (0000939767) (Filer)
8-K - EXELIXIS, INC. (0000939767) (Filer)